A Study to Evaluate the Safety and Efficacy of Nivolumab With Ipilimumab in Participants With Untreated Advanced Kidney Cancer Conducted in India

PHASE4CompletedINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

December 17, 2020

Primary Completion Date

January 4, 2024

Study Completion Date

January 4, 2024

Conditions
Kidney Neoplasms
Interventions
BIOLOGICAL

Nivolumab

Specified dose on specified days

BIOLOGICAL

Ipilimumab

Specified dose on specified days

Trial Locations (11)

110029

Local Institution - 0007, New Delhi

110085

Local Institution - 0017, Delhi

380054

Local Institution - 0005, Ahmedabad

400012

Local Institution - 0001, Mumbai

400053

Local Institution - 0016, Mumbai

411001

Local Institution - 0012, Pune

560017

Local Institution - 0006, Bangalore

560027

Local Institution - 0002, Karnataka

695011

Local Institution - 0011, Trivandrum

711103

Local Institution - 0019, Kolkata

400 057

Local Institution - 0013, Mumbai

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY